Dana dhuwit saben siji saham BiondVax Pharmaceuticals (SCNI)

Scinai Immunotherapeutics management is focused on developing advanced nanobodies for the therapy of immune pathologies. However, Scinai Immunotherapeutics faces early-stage research risks and a dependence on external financing. Meanwhile, production capacities remain steadily utilized by contract R&D orders and are undergoing modernization. Cash per share for the period demonstrates the current status of 5.63, reflecting the actual liquidity reserve.
Rincian metrik komprehensif lan analitis Scinai Immunotherapeutics Ltd (SCNI)

For Scinai Immunotherapeutics (SCNI), which develops nanobodies in Israeli laboratories, liquidity is critical for sustaining R&D cycles. This metric is calculated by dividing total cash reserves by the total number of shares outstanding. The trend in cash per share reflects the business's actual solvency reserve. An increase in this indicator confirms financial stability, whereas stagnation may signal underinvestment in assets. This allows for an assessment of the company's survival horizon without external financing.